

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-32 (canceled)

Claim 33 (new): A method for treatment or prevention of a vascular disease or states of tissue hypoperfusion with hypoxic or ischemic consequences in a patient, the method comprising the following steps:

selecting a substance from the group consisting of human apo-lactoferrin, human lactoferricin, peptides derivable from human lactoferrin, natural metabolites of human lactoferrin, and functionally equivalent analogues of human apo-lactoferrin;

determining a therapeutically effective amount of the selected substance;

administering the therapeutically effective amount of the selected substance to the patient

whereby the method is used as an alternative to bypass surgery or any therapeutic angiogenesis options.

Claim 34 (new): The method as recited in claim 33 whereby the method is used for treating impending stroke, manifested stroke, ischemic heart disease such as angina pectoris or impending or manifested myocardial infarction, and peripheral artery occlusive disease with or without impending gangrene.

Claim 35 (new): The method as recited in claim 33 whereby the method is used for treating vascular disease, state of tissue hypoperfusion, or state of depressed VEGF induced angiogenesis associated with peptic ulcer, leg ulcer or local or generalised hair loss.

Claim 36 (new): The method as recited in claim 33 wherein said substance is administered orally.

Claim 37 (new): The method as recited in claim 33 wherein said substance is administered parenterally.

Claim 38 (new): The method as recited in claim 33 wherein said substance is administered locally.

Claim 39 (new): The method as recited in claim 33 wherein said substance is administered by inhalation.

Claim 40 (new): A method for treatment or prevention of a vascular disease or states of tissue hypoperfusion with hypoxic or ischemic consequences in a patient, the method comprising the following steps:

selecting a peptide from the group consisting of peptides derivable from human lactoferrin;

determining a therapeutically effective amount of the selected substance;

administering the therapeutically effective amount of the selected substance to the patient

whereby the method is used as an alternative to bypass surgery or any therapeutic angiogenesis options.

Claim 41 (new): The method as recited in claim 40 wherein the peptide comprises a peptide constituted of all or some of the amino acids 12-40 of human lactoferrin counted from the N-terminal end, or a modified version thereof.

Claim 42 (new): The method as recited in claim 40 wherein the peptide comprises a peptide formed of the sequences constituted of amino acids 16-40 and amino acids 18-40 from the N-terminal end of human lactoferrin, or a modified version thereof.

Claim 43 (new): The method as recited in claim 40 wherein the peptide comprises a peptide essentially corresponding to residues 18-31 of human lactoferrin wherein C-20 is replaced by A, Q-22 is replaced by K, and N-26 is replaced by D.

Claim 44 (new): The method as recited in claim 40 wherein the peptide comprises a peptide formed of the amino acids in positions 12-31, counted from the N-terminal end, in the sequence constituting human lactoferrin, or a modification thereof, or a fragment thereof consisting of at least 7 amino acids.

Claim 45 (new): The method as recited in claim 40 wherein the peptide is a peptide consisting of 11-17 amino acids corresponding to the sequences that begin with one of the amino acids in positions 15-21 and end with the amino acid in position 31, counted from the N-terminal end, in the sequence constituting human lactoferrin, or a modification thereof.

Claim 46 (new): The method as recited in claim 40 wherein the peptide is a peptide consisting of 12 amino acids based on the sequence consisting of the amino acids in positions 20-31 in human lactoferrin, counted from the N-terminal end.

Claim 47 (new): The method as recited in claim 40 whereby the method is used for treating impending stroke, manifested stroke, ischemic heart disease such as angina pectoris or impending or manifested myocardial infarction, and peripheral artery occlusive disease with or without impending gangrene.

Claim 48 (new): The method as recited in claim 40 whereby the method is used for treating vascular disease, state of tissue hypoperfusion, or state of depressed VEGF induced angiogenesis associated with peptic ulcer, leg ulcer or local or generalised hair loss.

Claim 49 (new): The method as recited in claim 40 wherein said substance is administered orally.

Claim 50 (new): The method as recited in claim 40 wherein said substance is administered parenterally.

Claim 51 (new): The method as recited in claim 40 wherein said substance is administered locally.

Claim 52 (new): The method as recited in claim 40 wherein said substance is administered by inhalation.